SCHEMBL17874040

SCHEMBL17874040

Cc1ccc(S(=O)(=O)OC(N)C2CCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
ALDH1A1 P00352 2/20 0.43
ACHE P22303 1/20 0.43
CYP3A4 P08684 1/20 0.43
POLB P06746 1/20 0.42
CYP2D6 P10635 2/20 0.40
CYP1A2 P05177 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
ENPP3 O14638 2/20 0.39
ENPP1 P22413 2/20 0.39
ENPP2 Q13822 2/20 0.39
MCOLN3 Q8TDD5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14780181 0.84 TSHR (0.45) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL29132778 0.81 TSHR (0.43) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL4578793 0.81 ALDH1A1 (0.49) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL3451996 0.80 TSHR (0.42) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL6586026 0.79 ALDH1A1 (0.51) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL2754706 0.79 ALDH1A1 (0.51) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL21296440 0.79 ALDH1A1 (0.51) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL22260936 0.78 ACHE (0.43) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL4574789 0.78 ALDH1A1 (0.40) TSHRALDH1A1ACHECYP3A4POLB
SCHEMBL3454507 0.77 CYP2D6 (0.44) TSHRALDH1A1ACHECYP3A4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3393465-A1 METHODS OF TREATING PULMONARY DISEASES AND DISORDERS Proteostasis Therapeutics, Inc. (US) 2018-10-31 EP disclosed
EP-3237411-A2 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-11-01 EP disclosed
WO-2017112853-A1 METHODS OF TREATING PULMONARY DISEASES AND DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-06-29 WO disclosed
WO-2016105485-A2 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2016-06-30 WO disclosed